ClinicalTrials.Veeva

Menu

Glycemic Evaluation of Novel Staple Foods

N

National University of Singapore

Status

Completed

Conditions

Diabetes Mellitus
Diabete Type 2

Treatments

Dietary Supplement: Control Functional Foods
Dietary Supplement: Modified Functional Foods

Study type

Interventional

Funder types

Other

Identifiers

NCT05399134
2019/00952

Details and patient eligibility

About

In this study, the combined effects of functional foods (i.e. Anthocyanin fortified bread, Microfluidic co-flow noodles, 5ibrePlus™-fortified white rice) is investigated in an ad-libitum diet and their contributions to diabetes management.

Full description

Research has confirmed that a food's glycemic effect cannot be accurately predicted from the type and amount of carbohydrates it contains, as the rate at which the carbohydrates is digested and released into the bloodstream is influenced by many factors such as the food's physical form, its fat, protein and fibre content, and the chemical structure of its carbohydrates. For these reasons, it is possible to produce food from the same group with different effects on blood glucose. Consumption of low GI food has shown to improve glycemic control, lipid profile and reduce systemic inflammation. With bread, noodles and rice being the staple food for many Singaporeans, functional staple food alternatives offer a lower GI alternative without greatly affecting the population's dietary preference. Preliminary studies for each functional staple food alternative (for bread, noodles, and rice) had reflected improved glycaemic responses compared to their staple counterparts.

Enrollment

20 patients

Sex

All

Ages

21 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Chinese ethnicity
  • English-speaking
  • Age between 21 - 70 years old inclusive.
  • Confirmed Type 2 Diabetes with HbA1c level of less than 10%
  • Not on prandial insulin therapy
  • Subjects with stable medical problems not limited to hypertension and hyperlipidemia

Exclusion criteria

  • Current smoker or use of tobacco products within the 3 months

  • Vegetarian or other dietary restrictions that would not allow the subject to consume the test meal.

  • Persons with electronic medical implants (e.g. pacemaker).

  • Persons with known or ongoing psychiatric disorders or drug abuse within 3 years.

  • Women who are pregnant or lactating.

  • Persons with an average weekly alcohol intake that exceeds 21 units per week (males) and 14 units per week (females). 1 unit is equivalent to:

    • 12 oz or 360 mL of beer;
    • 5 oz or 150 mL of wine;
    • 1.5 oz or 45 mL of distilled spirits.
  • Persons with active infection(s) requiring systemic, antiviral or antimicrobial therapy that will not be completed prior to the first study visit

  • Persons who have undergone treatment with any investigational drug or biological agent within one (1) month of screening or plans to enroll in another study involving investigational drugs/biological agents during the duration of this study.

  • Persons with significant change in weight (+/- 5%) during the past month.

  • Persons with a known allergy to rice bran, dietary fiber, alginate and other study components (anthocyanins, soy protein).

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

None (Open label)

20 participants in 2 patient groups, including a placebo group

Modified Functional Foods (Treatment)
Experimental group
Description:
Anthocyanin black rice extract powder (ABREP)-fortified bread, microfluidic co-flow noodles, and 5ibrePlus™-fortified white rice for breakfast, lunch, and dinner respectively served in a mixed meal.
Treatment:
Dietary Supplement: Modified Functional Foods
Control Functional Foods (Control)
Placebo Comparator group
Description:
White bread, beehoon noodles, and jasmine white rice for breakfast, lunch, and dinner respectively served in a mixed meal.
Treatment:
Dietary Supplement: Control Functional Foods

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems